Corcept Therapeutics shares are trading higher after the company announced results from its phase 2 DAZALS trial of dazucorilant for amyotrophic lateral sclerosis.

Benzinga Newsdesk www.benzinga.com Positive 94.8%

Neg 0% Neu 0% Pos 94.8%

Comments

No comments yet. Be the first!